In a groundbreaking trial, an experimental gene therapy has restored functional hearing in 90% of patients with inherited deafness. The study, involving 42 participants including children and adults, demonstrated marked improvements in hearing ability over several years. Participants who received the therapy, targeting the OTOF gene responsible for otoferlin protein production, showed progressive hearing gains that stabilized around the one-year mark.
Ten participants monitored for at least two years can now hear normal conversation, with five detecting whispers. While four patients did not respond, researchers are optimistic about broader applications for various forms of genetic hearing loss. This therapy offers a potential one-time correction of the underlying genetic defect, contrasting with the mechanical nature and limitations of cochlear implants.
The therapy utilizes harmless viruses to deliver working copies of the OTOF gene to the inner ear, restoring hair cell function. Previous shorter trials confirmed its safety and efficacy in children. This latest study, including adults, confirmed duration of effect and broader patient applicability.
Participants under 18 generally showed greater improvement. The therapy not only enhanced hearing but also improved speech perception and production in some individuals. Researchers are now exploring multiple doses and longer-term outcomes, with potential for it to become a superior alternative to cochlear implants in certain aspects. Further trials are planned, with hopes for eventual U.S. FDA approval.